These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27043281)

  • 1. A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier.
    Kim DG; Bynoe MS
    J Clin Invest; 2016 May; 126(5):1717-33. PubMed ID: 27043281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine receptor signaling modulates permeability of the blood-brain barrier.
    Carman AJ; Mills JH; Krenz A; Kim DG; Bynoe MS
    J Neurosci; 2011 Sep; 31(37):13272-80. PubMed ID: 21917810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist.
    Gao X; Qian J; Zheng S; Changyi Y; Zhang J; Ju S; Zhu J; Li C
    ACS Nano; 2014 Apr; 8(4):3678-89. PubMed ID: 24673594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A2A Adenosine Receptor Regulates the Human Blood-Brain Barrier Permeability.
    Kim DG; Bynoe MS
    Mol Neurobiol; 2015 Aug; 52(1):664-78. PubMed ID: 25262373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
    Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of P-glycoprotein and Breast Cancer Resistance Protein Expression Induced by Focused Ultrasound-Mediated Blood-Brain Barrier Disruption: A Pilot Study.
    Conti A; Geffroy F; Kamimura HAS; Novell A; Tournier N; Mériaux S; Larrat B
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent Hypoxia and Its Impact on Nrf2/HIF-1α Expression and ABC Transporters: An in Vitro Human Blood-Brain Barrier Model Study.
    Zolotoff C; Voirin AC; Puech C; Roche F; Perek N
    Cell Physiol Biochem; 2020 Dec; 54(6):1231-1248. PubMed ID: 33326735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
    Miller DW; Hinton M; Chen F
    Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
    Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine receptor signaling: a key to opening the blood-brain door.
    Bynoe MS; Viret C; Yan A; Kim DG
    Fluids Barriers CNS; 2015 Sep; 12():20. PubMed ID: 26330053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A2A receptor activation reduces brain metastasis via SDF-1/CXCR4 axis and protecting blood-brain barrier.
    Chen L; Li L; Zhou C; Chen X; Cao Y
    Mol Carcinog; 2020 Apr; 59(4):390-398. PubMed ID: 32037613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.
    Agarwal S; Uchida Y; Mittapalli RK; Sane R; Terasaki T; Elmquist WF
    Drug Metab Dispos; 2012 Jun; 40(6):1164-9. PubMed ID: 22401960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
    Agarwal S; Elmquist WF
    Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Oct; 436(1-2):127-34. PubMed ID: 22688250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier.
    Sun A; Wang J
    Pharm Res; 2023 Nov; 40(11):2667-2675. PubMed ID: 37704894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease.
    Arduino I; Iacobazzi RM; Riganti C; Lopedota AA; Perrone MG; Lopalco A; Cutrignelli A; Cantore M; Laquintana V; Franco M; Colabufo NA; Luurtsema G; Contino M; Denora N
    Int J Pharm; 2020 Dec; 591():120011. PubMed ID: 33115695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
    Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
    PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.